Multicenter, randomized, controlled trial of S-1 monotherapy versus S-1 and interferon-α combination therapy for hepatocellular carcinoma with extrahepatic metastases-Reference-Cited by-同舟云学术

Multicenter, randomized, controlled trial of S-1 monotherapy versus S-1 and interferon-α combination therapy for hepatocellular carcinoma with extrahepatic metastases

Published:2018-03-12 Issue:9 Volume:48 Page:717-726
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Nagano Hiroaki¹²,Obi Shuntaro³,Hatano Etsuro⁴,Kaneko Shuichi⁵,Kanai Fumihiko⁶,Omata Masao⁶,Tsuji Akihito⁷,Itamoto Toshiyuki⁸,Yamamoto Kazuhide⁹,Tanaka Masatoshi¹⁰,Kubo Shoji¹¹,Hirata Koichi¹²,Nakamura Hideji¹³,Tomimaru Yoshito¹,Yamanaka Takeharu¹⁴,Kojima Shinsuke¹⁵,Monden Morito¹

Affiliation:

1. Department of Surgery, Graduate School of Medicine; Osaka University; Suita Japan

2. Department of Gastroenterological, Breast and Endocrine Surgery; Yamaguchi University Graduate School of Medicine; Ube Japan

3. Department of Gastroenterology and Hepatology; Kyoundo Hospital of the Sasaki Institute; Tokyo Japan

4. Department of Surgery, Graduate School of Medicine; Kyoto University; Kyoto Japan

5. Department of Gastroenterology; Kanazawa University Hospital; Kanazawa Japan

6. Department of Gastroenterology; University of Tokyo; Tokyo Japan

7. Department of Clinical Oncology; Kochi Health Science Center; Kochi Japan

8. Department of Surgery, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences; Hiroshima University; Hiroshima Japan

9. Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine; Dentistry and Pharmaceutical Sciences; Okayama Japan

10. Division of Gastroenterology, Department of Medicine; Kurume University School of Medicine; Kurume Japan

11. Department of Hepato-Biliary-Pancreatic Surgery; Osaka City University Graduate School of Medicine; Osaka Japan

12. Department of Surgery, Surgical Oncology & Science; Sapporo Medical University; Sapporo Japan

13. Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine; Hyogo College of Medicine; Nishinomiya Japan

14. Department of Biostatistics; Yokohama City University School of Medicine; Yokohama Japan

15. Translational Research Informatics Center; Foundation for Biomedical Research and Innovation; Kobe Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.13067/fullpdf

Reference40 articles.

1. Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence;Arii;J Hepatobiliary Pancreat Surg,1998

2. Rising incidence of hepatocellular carcinoma in the United States;El-Serag;N Engl J Med,1999

3. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years;Poon;Ann Surg,2001

4. Gastroenterological surgery in Japan: The past, the present and the future;Colvin;Ann Gastroenterol Surg,2017

5. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma;Minagawa;Ann Surg,2003

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma;World Journal of Surgical Oncology;2023-02-18

2. Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery;JAMA Surgery;2023-02-01

3. Interferon-α Research Progress in Prevention and Treatment of Hepatitis B Related Liver Cancer;Advances in Clinical Medicine;2023

4. Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021;Expert Opinion on Investigational Drugs;2022-05-26

5. Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma treated with Systemic Therapies;Clinical Cancer Research;2021-12-14